Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines-Reference-Cited by-同舟云学术

Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines

Published:2009-12 Issue:9707 Volume:374 Page:2115-2122
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Black Steven,Eskola Juhani,Siegrist Claire-Anne,Halsey Neal,MacDonald Noni,Law Barbara,Miller Elizabeth,Andrews Nick,Stowe Julia,Salmon Daniel,Vannice Kirsten,Izurieta Hector S,Akhtar Aysha,Gold Mike,Oselka Gabriel,Zuber Patrick,Pfeifer Dina,Vellozzi Claudia

Publisher

Elsevier BV

Subject

General Medicine

Reference42 articles.

1. Surveillance for safety after immunization: Vaccine Adverse Events Reporting System (VAERS)—United States, 1991–2001;MMWR Surveill Summ,2003

2. MMR vaccination and autism;Wakefield;Lancet,1999

3. Measles outbreaks in a population with declining vaccine uptake;Jansen;Science,2003

4. Nigerian states again boycott polio-vaccination drive;Kapp;Lancet,2004

5. Two unclear cases of death. Can we still recommend HPV vaccination?;Löwer;MMW Fortschr der Medizin,2008

Cited by 226 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and safety evaluation of a newly manufactured recombinant Baculovirus-Expressed quadrivalent influenza vaccine in adults 18 years old and Above: An Open-Label, phase III extension study;International Immunopharmacology;2024-07

2. Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring in South Korea;Journal of Health Informatics and Statistics;2024-05-31

3. What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety;Vaccine;2024-02

4. Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data;Vaccine;2024-02

5. Lessons learned from COVID-19, H1N1, and routine vaccine pharmacovigilance in the United States: a path to a more robust vaccine safety program;Expert Opinion on Drug Safety;2024-02